{"id":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","name":"Parker Hannifin Indego","slug":"parker-hannifin-exoskeleton","description":"Parker Hannifin Indego was a division of Parker Hannifin that developed the Indego powered lower-limb exoskeleton for individuals with spinal cord injuries. Licensed from [Vanderbilt university](/companies/vanderbilt-university) in 2012, the device received FDA clearance in March 2016 and CE Mark in November 2015, enabling users to stand and walk for up to four hours. Parker Hannifin sold the Indego business to Ekso Bionics in December 2022 for $10 million, exiting the exoskeleton market.","status":"active","founded":2012,"hq":"Cleveland, OH, USA","hqLat":41.4996574,"hqLng":-81.6936772,"hqGeocodedAt":"2026-08-05T14:43:06.985Z","hqAddress":null,"hqPrecision":null,"website":"https://www.parker.com","fundingTotal":null,"type":"hardware","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":54,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.indego.com/","title":"Indego","date_accessed":"2026-06-07"}],"keyFacts":[{"label":"Robot","value":"Powered lower limb exoskeleton for rehabilitation and personal use"},{"label":"Products","value":"Indego Therapy and Indego Personal"},{"label":"Parent","value":"Parker Hannifin Corporation (NYSE: PH)"},{"label":"Product","value":"Indego — powered lower-limb exoskeleton"},{"label":"Use case","value":"Spinal cord injury rehabilitation, mobility assistance"},{"label":"CEO","value":"Tom Williams (Chairman & CEO of Parker Hannifin)"},{"label":"Business unit head","value":"Achilleas Dorotheou (VP, Human Motion and Control)"},{"label":"CTO","value":"Mark Czaja (Chief Technology and Innovation Officer)"},{"label":"Technology origin","value":"Licensed from Vanderbilt University (2012)"},{"label":"FDA clearance","value":"March 2016"},{"label":"CE Mark","value":"November 2015"},{"label":"Acquired by","value":"Ekso Bionics (December 2022, $10M)"},{"label":"DOD study funder","value":"CDMRP/SCIRP (4-year multi-center study)"},{"label":"Clinical trial","value":"Largest US exoskeleton clinical trial, 1,200+ sessions, no serious adverse events"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-06-08T04:05:18.726Z","updatedAt":"2026-08-21T22:27:04.850Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/parker-hannifin-exoskeleton","url":"https://registry.deploy.report/companies/parker-hannifin-exoskeleton","name":"Parker Hannifin Indego","description":"Parker Hannifin Indego was a division of Parker Hannifin that developed the Indego powered lower-limb exoskeleton for individuals with spinal cord injuries. Licensed from [Vanderbilt university](/companies/vanderbilt-university) in 2012, the device received FDA clearance in March 2016 and CE Mark in November 2015, enabling users to stand and walk for up to four hours. Parker Hannifin sold the Indego business to Ekso Bionics in December 2022 for $10 million, exiting the exoskeleton market.","identifier":"bc532371-0bd2-47c6-9edc-7f5f701b2a24","foundingDate":"2012","address":"Cleveland, OH, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}